FDA Approves Entresto for Heart Failure

Share this content:
FDA Approves Entresto for Heart Failure
FDA Approves Entresto for Heart Failure

WEDNESDAY, July 8, 2015 (HealthDay News) -- The U.S. Food and Drug Administration on Tuesday approved the drug Entresto (sacubitril/valsartan) to treat heart failure.

Entresto was evaluated in clinical trials involving more than 8,000 adults. It was shown to reduce the rate of cardiovascular death and hospitalization, compared to the drug enalapril. Most clinical trial participants were taking currently approved medications for heart failure, including β-blockers, diuretics, and mineralocorticoid antagonists.

Common side effects of Entresto included hypotension, hyperkalemia, and renal impairment, according to the agency. A more serious adverse effect was angioedema. Blacks and those with a history of angioedema are at higher risk of this reaction, the FDA said. Entresto should not be used with any angiotensin converting enzyme inhibitor, which would increase a user's risk of angioedema. And women should discontinue Entresto as soon as possible if they become pregnant, the FDA warned.

"Heart failure is a leading cause of death and disability in adults," Norman Stockbridge, M.D., Ph.D., director of the division of cardiovascular and renal products in the FDA's Center for Drug Evaluation and Research, said in a statement. "Treatment can help people with heart failure live longer and enjoy more active lives."

Entresto is produced by Novartis, based in East Hanover, N.J.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

California Lawsuit Claims AbbVie Paid Doctors to Prescribe Humira

California Lawsuit Claims AbbVie Paid Doctors to Prescribe ...

Claims physicians prescribed Humira because of financial kickbacks, not as best drug for patient

Patient-Directed IV Remifentanil Cuts Epidural Conversions

Patient-Directed IV Remifentanil Cuts Epidural Conversions

Patient-controlled remifentanil reduces proportion of conversions versus intramuscular pethidine

Pediatricians Have Role in Supporting Transgender Youth

Pediatricians Have Role in Supporting Transgender Youth

Recommendations developed for comprehensive care for youth identifying as transgender, gender diverse

is free, fast, and customized just for you!




Already a member?

Sign In Now »